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Abstract
Background: Elevated non-esterified fatty acids (NEFA) concentrations in non-pregnant animals have been reported to
decrease pancreatic responsiveness. As ovine gestation advances, maternal insulin concentrations fall and NEFA
concentrations increase. Experiments were designed to examine if the pregnancy-associated rise in NEFA concentration
is associated with a reduced pancreatic sensitivity to glucose in vivo. We investigated the possible relationship of NEFA
concentrations in regulating maternal insulin concentrations during ovine pregnancy at three physiological states, non-
pregnant, non-lactating (NPNL), 105 and 135 days gestational age (dGA, term 147+/- 3 days).
Methods: The plasma concentrations of insulin, growth hormone (GH) and ovine placental lactogen (oPL) were
determined by double antibody radioimmunoassay. Insulin responsiveness to glucose was measured using bolus injection
and hyperglycaemic clamp techniques in 15 non-pregnant, non-lactating ewes and in nine pregnant ewes at 105 dGA and
near term at 135 dGA. Plasma samples were also collected for hormone determination. In addition to bolus injection
glucose and insulin Area Under Curve calculations, the Mean Plasma Glucose Increment, Glucose Infusion Rate and Mean
Plasma Insulin Increment and Area Under Curve were determined for the hyperglycaemic clamp procedures. Statistical
analysis of data was conducted with Students t-tests, repeated measures ANOVA and 2-way ANOVA.
Results: Maternal growth hormone, placental lactogen and NEFA concentrations increased, while basal glucose and
insulin concentrations declined with advancing gestation. At 135 dGA following bolus glucose injections, peak insulin
concentrations and insulin area under curve (AUC) profiles were significantly reduced in pregnant ewes compared with
NPNL control ewes (p < 0.001 and P < 0.001, respectively). In hyperglycaemic clamp studies, while maintaining glucose
levels not different from NPNL ewes, pregnant ewes displayed significantly reduced insulin responses and a maintained
depressed insulin secretion. In NPNL ewes, 105 and 135 dGA ewes, the Glucose Infusion Rate (GIR) was constant at
approximately 5.8 mg glucose/kg/min during the last 40 minutes of the hyperglycaemic clamp and the Mean Plasma Insulin
Increment (MPII) was only significantly (p < 0.001) greater in NPNL ewes. Following the clamp, NEFA concentrations
were reduced by approximately 60% of pre-clamp levels in all groups, though a blunted and suppressed insulin response
was maintained in 105 and 135 dGA ewes.
Conclusions: Results suggest that despite an acute suppression of circulating NEFA concentrations during pregnancy,
the associated steroids and hormones of pregnancy and possibly NEFA metabolism, may act to maintain a reduced insulin
output, thereby sparing glucose for non-insulin dependent placental uptake and ultimately, fetal requirements.
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Background
To meet the increasing fetal demands and maternal energy
requirements of pregnancy, alterations in the partitioning
and utilization of maternal nutrients must occur. These
adaptations are regulated by changing blood concentra-
tions of regulatory metabolites and hormones, together
with changes in target tissue responsiveness. Of principle
interest are alterations in maternal glucose metabolism
during pregnancy, as glucose is a major limiting nutrient
of fetal growth [1,2]. As sheep pregnancy advances, circu-
lating maternal insulin concentrations decline [3,4] and
the insulin response to a glucose load is significantly
reduced [5,6]. These decreased insulin concentrations
during the last third of gestation and into lactation in
ruminants have been postulated to be the result of the
decreased response of the pancreas to insulinotropic
agents [7]. Reducing insulin secretion during pregnancy is
proposed to be beneficial to fetal well-being, through the
creation of an environment which supports minimizing
peripheral glucose utilization and maximizing glucose
extraction of the gravid uterus [8,9]. Additionally, the sen-
sitivity of peripheral tissues to insulin is reduced [10,11]
and increased mobilization of adipose tissue to supply
non-esterified fatty acids (NEFA) as an alternative mater-
nal energy source occurs [12-15]. This pregnancy induced
mobilization of adipose tissue is accompanied by a
decline in lipid synthesis, and occurs as a result of altera-
tions in insulin receptor numbers, a decreased circulating
insulin concentration, as well as interactions with specific
hormones of pregnancy [16,17].
High plasma NEFA concentrations have been associated
with the development of insulin resistance in the periph-
eral tissues and also the β-cell [18]. Elevated NEFAs in the
muscle inhibit glucose disposal through interactions with
the insulin signaling pathways, as certain lipid species act
as secondary messengers (ceramide, diacylglycerol and
hexosamine), inhibiting insulin signaling [19,20]. Altered
serine/threonine phosphorylation of insulin substrate-1
and direct inhibition of components such as protein
kinase B, are also sites of action through which NEFAs
may give rise to decreased insulin signaling [20,21]. Sev-
eral of these steps, including the insulin receptor substrate
-1 association with phosphatidylinositol, are reduced in
liver and muscle during pregnancy [22]. Furthermore, car-
diac function is impaired in situations of elevated cera-
mide, through apoptotic pathways [23]. With regards to
the pancreas, elevated NEFA concentrations in rats have
been reported to decrease pancreatic responsiveness,
resulting in a reduction in glucose stimulated insulin
secretion [24-26]. In studies with male rat pancreas, fol-
lowing 48 hours of incubation with elevated NEFA con-
centrations, glucose-induced insulin secretion, as well as
proinsulin biosynthetic responses, are reduced [24,26]. In
addition, there is a body of evidence which suggests that
chronically elevated NEFA concentrations have a lipotoxic
effect on the pancreas, through the formation of nitric
oxide and β-cell apoptosis [18,19,27,28].
Studies investigating a possible interaction between
increasing NEFA concentrations and maternal pancreatic
sensitivity during ovine pregnancy have not yet been
reported. The following experiments were designed to
examine whether the pregnancy-associated rise in NEFA
concentration is associated with a reduced pancreatic sen-
sitivity to glucose in vivo. Reported here are in vivo preg-
nant sheep studies of insulin responsiveness to glucose,
measured using bolus injection and hyperglycemic clamp
techniques.
Methods
Animals and experimental design
Twenty-four 3–4 year old, pen-trained Merino ewes of a
known gestational age were used. The experiments were
conducted adhering to the National Health and Medical
Research Council (NH&MRC) guidelines as administered
and approved by the University of Western Sydney,
Hawkesbury Animal Care and Ethics Committee and the
Commonwealth Scientific Research Organization, Divi-
sion of Animal Production, Animal Care and Experimen-
tation Ethics Committee. All animals displaying estrus
following a program of synchronised mating induced by
pre-treatment with intravaginal progestogen pessaries
were recorded. Pregnancy was later verified by rectal ultra-
sound scanning at 28 dGA, and then confirmed together
with litter size determination at 65 dGA, using abdominal
ultrasound. Those ewes displaying estrus, but failing to
conceive were used in a non-pregnant, non-lactating
(NPNL) control group. A total of 15 NPNL ewes and nine
pregnant ewes, three single bearing and six twin bearing,
were used in this study. At 90 dGA a trial glucose bolus
injection study was conducted in four ewes. At 105 dGA,
all animals were studied (total n = 9), in both glucose
bolus and hyperglycaemic protocols and then subse-
quently again at 135 dGA. At each gestational age, NPNL
ewes (n = 15) were also studied under both protocols,
expect at 90 dGA were only the bolus studies were con-
ducted and only 5 NPNL animals studied.
One week prior to the commencement of the experimen-
tal period, ewes were weighed. Body weights (BW) were
used to determine the glucose bolus doses to be adminis-
tered at study (0.4 g glucose/kg). Animals were then indi-
vidually penned under natural lighting conditions and fed
700 g/d per animal, of a 60:40 pelleted ration, consisting
of 60% hammer milled lucerne and 40% hammer milled
oaten chaff (92.7 ± 0.34 % dry matter (DM), 68.9 ± 1.05%
digestible organic matter, and having a calculated metab-
olizable energy content of 10.33 ± 0.2 MJ/kg DM, crudeReproductive Biology and Endocrinology 2004, 2:64 http://www.rbej.com/content/2/1/64
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protein content of 13.8 ± 0.5%). Water was freely availa-
ble at all times.
Glucose Treatments
The ewes were subjected to an experiment protocol con-
sisting of two procedures, 1) a bolus glucose study and 2)
a hyperglycaemic clamp study. Each experimental period
extended over 5 days, with 2 days in between the proce-
dures. On the day before the commencement of the bolus
glucose study, each ewe had polyvinyl jugular vein cathe-
ters inserted bilaterally under local anaesthesia. Catheters
were maintained patent with daily-heparinized saline
flushes (35 U heparin/ml). The bolus glucose procedure
was conducted as follows. On the day of the experiment,
following a 24-h fast, two pre-injection (basal concentra-
tion) blood samples were collected 15 min apart. Imme-
diately following the second basal sample, a glucose bolus
was administered. Seven two ml blood samples were col-
lected at 5, 10, 20, 35, 55, 155 and 215 min post-injection
and stored in an ice bath until centrifuged at 1,200 × g for
15 min at 4°C. A 0.5 ml aliquot of supernatant was
removed for glucose determination, while the remaining
plasma was frozen at -20°C for later biochemical analysis.
Two days after the bolus glucose injection study, animals
were also subjected to a 120 min hyperglycaemic clamp
procedure, which was imposed after a 24 h fast [29]. Prior
to the commencement of the clamp, three pre-infusion
samples were taken 15 min apart (T -30, T -15 and T 0)
through the right jugular catheter. At T 0, a bolus glucose
injection was administered through the left jugular cathe-
ter and then individual peristaltic pumps were activated to
begin the glucose infusion through the left jugular cathe-
ter. Blood samples (3.0 ml) were then collected every 5
min from the right jugular catheter. To maintain glucose
at the bolus injection level, a spot sample of blood was
taken from each 5 min sample and glucose concentration
determined using a Boehringer Mannheim Accutrend®
blood glucose monitoring kit (Boehringer Germany). The
pump speed setting was then adjusted to maintain the
required blood glucose concentration. Samples were col-
lected for analysis as described for the bolus protocol.
Assays and calculations
The plasma concentrations of insulin, growth hormone
(GH) and ovine placental lactogen (oPL) were deter-
mined by double antibody radioimmunoassay as previ-
ously described [30]. Insulin measurements were made
for every collection point, while GH and oPL were deter-
mined from the pooled pre-bolus samples. Plasma glu-
cose and NEFA concentrations were determined as
previously described [31,32]. While glucose samples were
determined at each sample point, samples for NEFA con-
centration during the hyperglycaemic clamp studies were
collected at T -30 and T 0 and at 85 and 90 min relative to
the imposition of the clamp. Inter-assay and intra-assay
co-efficients of variation for low and high quality control
samples for all assays are detailed. Insulin;  Inter-assay
LQC, 5.2, HQC, 3.9 and intra-assay LQC, 5.7, HQC, 7.3.
GH; Inter-assay LQC 10.3, HQC 7.9, and intra-assay LQC
8.6, HQC 7.5.oPL; Inter-assay LQC 9.1, HQC 12.0, and
intra-assay LQC 9.2, HQC 10.9. Glucose; Inter-assay LQC
10.1, HQC 9.3, and intra-assay LQC 10.3, HQC 11.9.
NEFA; Inter-assay LQC 11.4, HQC 7.8, and intra-assay
LQC 10.6, 6.7.
Data from the bolus glucose injection studies were
expressed using the following parameters;
- Area under curve (AUC), for both the glucose ((mg/ml)/
min) and insulin ((ng/ml)/min) response profiles,
- Glucose clearance rate (CLR; ml/min)
- Glucose half life (t1/2, min)
AUC for both the glucose and the resulting insulin
response profiles were calculated using the trapezoidal
rule. Glucose clearance rate (CLR, ml/min) was calculated
as Glucose dose /AUC. Glucose and insulin half-life was
determined from the interpolated cumulative response
curve. Glucose and insulin concentrations at 10 minutes
were used as the peak response. In the hyperglycaemic
clamp studies, in addition to AUC calculations for the
whole study period, the Mean Plasma Glucose Increment
(MPGI, mg/dl), Glucose Infusion Rate (GIR; g (glucose)/
kg BW/min) and Mean Plasma Insulin Increment (MPII;
ng/ml) were determined over the last 40 min of the clamp
[29], during the GIR steady state period. These results were
averaged for each animal, and then pooled to give group
results.
Statistical analyses
There was no significant time of experiment effect when
comparing NPNL ewe data collected at each of the gesta-
tional age studied, and as a consequence NPNL data from
studies at 90, 105 and 135 dGA were pooled and analysed
as a single control group against each gestational age
group. No differences were found between the singleton
and twin bearing ewes and litter size data were pooled to
give one pregnant animal group at 105 and 135 dGA (n =
9). Glucose data from the 90, 105 and 135 dGA bolus glu-
cose and 105 and 135 dGA hyperglycaemic clamp experi-
ments were analysed through repeated measures ANOVA
with Greenhouse Geisser adjustment [33]. Between ewe
variation was included in the ANOVA model. In the
hyperglycaemic clamp studies T0 and baseline measure-
ments were used as co-variates. Glucose and insulin AUC,
peak concentrations, t1/2 and CLR data from the bolus
glucose injection studies were further analysed using theReproductive Biology and Endocrinology 2004, 2:64 http://www.rbej.com/content/2/1/64
Page 4 of 10
(page number not for citation purposes)
following orthogonal contrasts of a), NPNL versus preg-
nant ewes; b) day 90 versus day 105 and day 135 ewes and
c) day 105 versus day 135. Body weights, glucose doses,
insulin, GH, oPL and NEFA concentrations and the
derived variables of GIR, MPII and MPGI were all ana-
lysed using two sample unpaired Student's t-tests.
Changes in NEFA concentrations following hyperglycae-
mic clamp treatment at three different physiological
states, NPNL, 105 dGA and 135 dGA was analysed using
2 way ANOVA.
Results
Pre experimental body weights, glucose and insulin 
concentrations
There were no significant differences in body weight
(Mean weight: 48.4 ± 1.8 kgs) and required glucose bolus
injection (19.5 ± 0.7 g) across the physiological states
studied. In the bolus glucose experiments, the basal glu-
cose concentration was significantly lower in pregnant
ewes measured on day 135 than on day 90 of gestation (p
< 0.05). Basal glucose concentrations in the clamp studies,
at 105 and 135 dGA, were also significantly reduced com-
pared to NPNL concentrations (p < 0.05, Table 1). The
basal insulin concentrations as gestation advanced
declined, and basal levels measured at 105 and 135 days
gestation were significantly reduced compared to NPNL
concentrations in both experimental treatments (p < 0.05,
Table 1).
Bolus glucose studies
Glucose injection significantly increased glucose concen-
trations in all groups compared to basal levels (Figure 1a,
p < 0.001). After co-variate adjustment for basal glucose
concentration, repeated measure ANOVA of glucose con-
centration after bolus injection revealed no significant dif-
ferences in maximal glucose concentration obtained
between pregnant and NPNL ewes. There was no differ-
ence for glucose AUC between NPNL and pregnant ewes,
nor did CLR and t1/2 differ between NPNL and pregnant
ewes (Table 2).
Whereas peak insulin concentrations and the insulin AUC
profiles were significantly reduced in pregnant compared
with NPNL ewes (Figure 1b, p < 0.001 and Table 3). Day
135 ewes had significantly reduced peak insulin responses
compared to day 105 ewes (Table 3, p < 0.04). Ewes at 105
and 135 dGA had significantly reduced AUC when com-
pared to day 90 ewes (Table 3, p < 0.001). The decline in
AUC was linearly related to stage of pregnancy, whilst
insulin t1/2 did not vary significantly across the groups
(Table 3).
Hyperglycaemic clamp studies
The bolus glucose injection, prior to the start of the clamp,
significantly elevated glucose concentrations in all groups
(Table 1 and Figure 2a, p < 0.001). Following adjustment
for basal differences, the glucose concentrations obtained
were not statistically different between pregnant and
NPNL ewes or between days of gestation. Pregnant ewes
while having glucose concentrations not different from
NPNL ewes had significantly reduced insulin responses
and continued depressed insulin secretion over the 2
hours of the study (Figure 2b, p < 0.001). The measured
insulin AUC (ng/ml)/min), were significantly reduced
over gestation in 105 dGA and 135 dGA ewes compared
to NPNL ewes (NPNL; 1675 ± 110 vs. 105 dGA; 491 ± 67
and 135 dGA; 427 ± 55, p < 0.001).
Mean plasma glucose increment (MPGI), glucose infusion 
rate (GIR) and Mean plasma insulin increment (MPII)
The MPGI did not differ significantly between the three
physiological states examined (Table 4). Despite a slight
rise in glucose concentrations during the clamp, the
amount of glucose required to maintain glucose concen-
trations constant, declined from approximately 14 to 6
(a) Plasma glucose (mg/dl) and (b) insulin concentrations (ng/ ml) following a bolus glucose injection (0.4 g/kg) in NPNL  ewes (, n = 15) and pregnant ewes, 90 (×, n = 4), 105 (∆, n  = 9) 135 (■ , n = 9) dGA Figure 1
(a) Plasma glucose (mg/dl) and (b) insulin concentrations (ng/
ml) following a bolus glucose injection (0.4 g/kg) in NPNL 
ewes (, n = 15) and pregnant ewes, 90 (×, n = 4), 105 (∆, n 
= 9) 135 (■ , n = 9) dGA.
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mg glucose/kg/min (Figure 2c). A steady state infusion
point was obtained in the last 40 min of the clamp. GIR
during this period was constant, at approximately 5.8 mg
glucose/kg/min, across all physiological states (Table 4).
Although MPII during the last 40 min of the glucose
hyperglycaemic infusion was significantly greater in
NPNL ewes, than in the day 105 and 135 groups (Table 4,
p < 0.001), the glucose infusion rates necessary to main-
tain hyperglycemia within the groups was not signifi-
cantly altered (Table 4).
GH, oPL and NEFA concentrations
Pre-bolus pooled samples for maternal GH and oPL con-
centrations displayed increased concentrations with
gestational age. Maternal GH concentrations increased
with gestation, rising significantly from 0.78 ± 1.1 ng/ml
in the NPNL state (p < 0.05), to 2.13 ± 0.35 ng/ml at 105
dGA and 3.5 ± 0.9 ng/ml at 135 dGA. Placental lactogen
concentrations were 579 ± 74 ng/ml at 105 dGA and
increased to 1211 ± 144 ng/ml (p < 0.05) by 135 dGA.
Both pregnant groups displayed higher NEFA concentra-
tions than did the NPNL control ewes following a 24-h
fast (Figure 3). Pre-fasting, pre-clamp NEFA concentra-
tions at day 105 were significantly greater than those of
Table 1: Basal glucose (mg/dl) and insulin (ng/ml) concentrations for both bolus glucose injection and hyperglycaemic clamp studies at 
four gestation age groups. Within columns values with different superscripts are significantly different at p < 0.05 and (n) = number of 
animals.
Glucose Insulin
Bolus Clamp Bolus Clamp
NPNL (15) 46.9 ± 1.7a 51.1 ± 1.9a 0.89 ± 0.13a 1.09 ± 0.10a
90 dGA (4) 40.1 ± 4.8ab 0.64 ± 0.05ab
105 dGA (9) 29.1 ± 4.0bc 38.6 ± 3.0b 0.49 ± 0.11bc 0.53 ± 0.06b
135 dGA (9) 21.3± 1.9c 40.6 ± 4.9b 0.29 ± 0.07c 0.36 ± 0.06b
Table 2: Glucose peaks (mg/dl), AUC (mg/ml)/min), clearance rate (CLR, ml/min) and half life (t1/2, min) for NPNL (n = 15) ewes and 
pregnant ewes, 90 (n = 4), 105 (n = 9), and 135 (n = 9) dGA following bolus glucose injection.
Glucose peak AUC CLR t1/2
NPNL 244.9 ± 6.1 166.46 ± 10.2 129.9 ± 7.8 49.6 ± 2.9
90 dGA 239.3 ± 21.9 162.0 ± 18.5 124.42 ± 11.9 50.9 ± 3.8
105 dGA 192.5 ± 12.1 131.4 ± 9.7 149.1 ± 6.7 48.2 ± 3.2
135 dGA 203.4 ± 9.6 162.4 ± 11.4 123.4 ± 8.4 57.4 ± 2.5
Table 3: Peak insulin responses (ng/ml), AUC ((ng/ml)/min) and half life (t1/2, min) for NPNL (n = 15) ewes and pregnant ewes 90 (n = 
4), 105 (n = 9) and 135 (n = 9) dGA following bolus glucose injection.
Peak AUC t1/2
NPNL 13.5 ± 1.4 1095.3 ± 112.8 60.7 ± 4.1
90 dGA 6.9 ± 2.0 458.8 ± 48.9 61.9 ± 12.2
105 dGA 4.7 ± 0.8 277.5 ± 60.3 45.7 ± 7.2
135 dGA 2.5 ± 0.5 169.9 ± 24.9 68.9 ± 10.8Reproductive Biology and Endocrinology 2004, 2:64 http://www.rbej.com/content/2/1/64
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NPNL ewes (p < 0.05, Figure 3). Ewes at 135 dGA dis-
played significantly elevated NEFA concentrations com-
pared to NPNL NEFA concentrations (P < 0.001, Figure
3), and higher concentrations than at 105 dGA (p < 0.06).
Following the 2 hour hyperglycaemic clamp, NEFA con-
centrations were reduced to levels 54% of pre-clamp levels
in NPNL ewes, 59% in day 105, and 58% in day 135 ewes
(Figure 3). Circulating NEFA concentrations in 105 dGA
ewes following the hyperglycaemic clamp were not signif-
icantly different from NPNL concentrations, nor were
they different from post clamp 135 dGA concentrations,
though 135 dGA post clamp concentrations remained ele-
vated above NPNL concentrations (p < 0.05, Figure 3).
Discussion
There are two important findings of these studies. Firstly,
circulating maternal insulin concentration and glucose-
stimulated insulin release decrease as gestation advances.
Secondly, the imposition of a two-hour hyperglycaemic
clamp in pregnant ewes reduces NEFA concentrations, to
concentrations not different form the pre clamp concen-
trations of fasted non-pregnant non-lactating ewes,
though despite the reduction, insulin response to glucose
remains depressed in 105 and 135 dGA ewes. These
results are in agreement with the blunted insulin release
during a hyperglycemic clamp treatment observed in lac-
tating cattle, where NEFA concentrations are also elevated
late in gestation, prior to a clamp [29,34]. Glucose-stimu-
lated insulin release over gestation in our report was
assessed by the capacity of the maternal pancreas to
release insulin in response to two forms of glucose
challenge. Both of these challenges confirmed that by the
end of the second third of gestation (105 dGA, term 147
dGA), a significant and maintained depression in insulin
release in the light of elevated glucose levels was observed,
which was repeated near term (135 dGA). This suppres-
sion of glucose stimulated insulin release was accompa-
nied by increases in maternal NEFA, GH and oPL
concentrations.
Lipid metabolism during pregnancy has two distinct
phases. The first two thirds of pregnancy are characterised
by a low lipolytic activity and the majority of maternal
energy appears to be derived from dietary carbohydrate.
During the later part of pregnancy and into lactation,
there is an increased level of lipolytic activity resulting in
increased NEFA concentrations [17], which serve as an
alterative energy source, reducing maternal peripheral
reliance upon glucose [12,13]. Under these increasing
rates of lipolysis, the whole body glycemic response to
insulin changes to conserve glucose for uterine uptake and
fetal growth [13] and maternal insulin concentrations
decline [3,4]. NEFAs are well documented to promote glu-
cose stimulated insulin secretion [35,36,36], however, the
chronic effects of elevated NEFA concentrations,
specifically as occur during pregnancy, are ill defined, and
may be associated with suppressed glucose stimulated
insulin release [25]. The responsiveness of the male pan-
creas has been reported to be decreased following expo-
sure to elevated NEFA concentrations for periods from 3
up to 48 hours [24-26]. In the pregnancy studies pre-
sented here, a two-hour hyperglycaemic clamp at two
time points in the later half of gestation, reduced NEFA
concentrations by approximately 50%, but maternal insu-
lin release in response to glucose remained suppressed.
This is in contrast to the same protocol in NPNL ewes,
(a) Plasma glucose (mg/dl), (b) insulin concentrations (ng/ml)  and (c) glucose infusion rates (mg glucose/kg/min) during a  hyperglycaemic clamp conducted on NPNL ewes (, n = 15)  and pregnant ewes at 105 (∆, n = 9) 135 (■ , n = 9) dGA Figure 2
(a) Plasma glucose (mg/dl), (b) insulin concentrations (ng/ml) 
and (c) glucose infusion rates (mg glucose/kg/min) during a 
hyperglycaemic clamp conducted on NPNL ewes (, n = 15) 
and pregnant ewes at 105 (∆, n = 9) 135 (■ , n = 9) dGA.
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where NEFA concentrations were also reduced, though
pancreatic insulin response was maintained. It is interest-
ing to note that the NEFA concentrations before the clamp
in NPNL ewes were similar to pregnant ewes' NEFA con-
centrations at the end of the clamp procedure, and yet the
NPNL insulin response remained unaltered and NPNL
NEFA concentrations had declined by approximately
50%. In contrast, in the pregnant ewes, insulin release
remained suppressed, despite a comparable depression in
NEFA concentrations as generated in the NPNL ewes,
similar to NPNL pre-clamp NEFA concentrations. Some-
what similar studies have been conducted in fed and
fasted non-pregnant mice [36]. When a hyperglycaemic
clamp was imposed, NEFA concentrations were reduced.
While fasted animals had a normal first phase insulin
release, similar to the fed animals, this response fell away
and significantly reduced insulin secretion rates were
observed [36]. The interesting differences between these
mice studies and the pregnant sheep response, is that the
initial insulin response is also blunted in pregnancy, sug-
gesting other effects of fasting and or pregnancy are
involved in this absolute suppression of a glucose stimu-
lated insulin response.
These data demonstrate that the acute suppression of
NEFA concentrations per se during pregnancy does not
result in the restoration of a NPNL-like insulin response.
This suggests that possibly other factors of pregnancy,
such as the influence of lactogenic and steroid hormones,
and NEFA metabolism may be acting upon the maternal
pancreas to suppress the maternal insulin response during
pregnancy in sheep. Placental lactogens have been docu-
mented in many mammalian species, including the sheep
and human, and PL concentrations increase with advanc-
ing gestational age, reaching maximal concentrations just
prior to term [37,38], similar to what is reported in this
study. Homologous studies with human placental lac-
togen, prolactin and growth hormone have shown signif-
icantly elevated in vitro secretion of insulin from
pancreatic islets [39]. Interestingly, more recently it has
been suggested that PL and placental GH act in concert to
modulate maternal metabolism, resulting in an increase
in the available supply of glucose and amino acids to the
fetus [9]. Studies concerning the effect sheep PL may have
on pancreatic function however, are not definitive [40-
42]. The short-term removal of oPL by immunoneutrali-
sation increased insulin concentration [42], while an
acute oPL infusion failed to demonstrate any significant
changes in insulin levels [41]. However, in the carunculec-
tomy model of fetal growth restriction (FGR), carunculec-
tomised ewes have increased glucose concentration,
without any increase in insulin [40], suggesting that there
may be a pregnancy-specific impairment of insulin secre-
tion during sheep pregnancy.
Table 4: Mean plasma glucose increment (MPGI, mg/dl), glucose infusion rates (GIR, mg glucose/kg/min) and mean plasma insulin 
increments (MPII, ng/ml) during the last 40 min of hyperglycemic clamp for NPNL (n = 15) ewes and pregnant ewes at 105 (n = 9) and 
135 (n = 9) dGA. Within columns values with different superscripts are significantly different at p < 0.05.
MPGI GIR MPII
NPNL 368.3 ± 12.5a 5.58 ± 0.39a 16.44 ± 1.1a
105 dGA 344.1 ± 24.8a 6.03 ± 0.51a 5.1 ± 0.61b
135 dGA 354.4 ± 16.2a 5.66 ± 0.71a 5.03 ± 0.74b
Post fast circulating NEFA concentrations (µmol/L), pre (■ )  and post () the imposition of a hyperglycaemic clamp at  three physiological states, NPNL (n = 15), day 105 (n = 9)  and day 135 (n = 9) ewes Figure 3
Post fast circulating NEFA concentrations (µmol/L), pre (■ ) 
and post () the imposition of a hyperglycaemic clamp at 
three physiological states, NPNL (n = 15), day 105 (n = 9) 
and day 135 (n = 9) ewes. Comparisons are by 2-way 
ANOVA compared to NPNL post fasting pre-hyperglycaemic 
clamp NEFA concentrations, * p < 0.05, **p < 0.01 and *** p 
< 0.001.
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Placental progesterone has also been reported to play a
major role in modulating insulin release during preg-
nancy. In rat islet studies, progesterone counteracts lac-
togenic insulin stimulatory behaviour [43], and
circulating progesterone levels in the sheep increase from
approximately 50 dGA [38,44]. Possible differential and
interactive effects of ovine PL and progesterone on insulin
secretion as gestation advances, as observed in the rat
[43,45], remain to be fully explored. Despite this fact,
changes in adipose tissue insulin sensitivity suggest that in
pregnancy, insulin resistance may develop together with a
change in the pattern of substrate utilization, which occur
under rising progesterone, prolactin, PL and GH concen-
trations [9,13,46]. Actions of GH on adipose tissue
include inhibition of insulin-induced fatty acid synthesis
[47]. Also a down-regulation of GLUT-1 and GLUT-4 in
vivo, in rat adipocyte plasma membranes incubated with
GH, has resulted in a reduced adipocyte glucose uptake
[48], associated with a down regulation of insulin sensi-
tivity or responsiveness. In addition, despite initial
experiments reporting that GH and oPL do not modulate
lipolytic activity [17], there is evidence to suggest PL and
prolactin decrease adipocyte glucose transport [49] and
that oPL may act in concert with GH, enhancing GH
effects on the pattern of substrate utilization [9,50].
Another candidate that presents itself as possibly regulat-
ing maternal insulin response is that of leptin. Leptin con-
centrations rise during pregnancy [51], and stimulates
lipolysis in muscle tissues [52], and may also be involved
in a unique form of lipolysis where glycerol is released
instead of NEFAs [53]. A direct role of action upon human
and rat islet cells has been demonstrated in culture and in
vivo, through actions in the regulation of Ca2+ influx into
the β-cell [54,55]. However, when leptin was adminis-
tered to fasted mice there were no observed changes in
plasma insulin or glucose concentrations [54], suggesting
other factors in a fasted state act to regulate pancreatic
insulin release in response to glucose. Leptin concentra-
tions were not determined in the study reported here, but
the relationship between elevated leptin levels during
pregnancy and pancreatic responsiveness is an interesting
one, and one that requires further study in vivo. One final
possible explanation of the data reported here could be
that the chronic elevation in NEFA levels, as occurs in
pregnant ewes, does play a role. While the acute
suppression of NEFA concentrations during pregnancy
did not result in the restoration of a NPNL-like insulin
response, a chronic exposure to elevated NEFAs imparts a
continuous 'lipotoxic' inhibitory effect. Increased NEFA
concentrations have been associated with a lipotoxic
effect on the pancreas resulting in suppressed insulin
release and β-cell apoptosis, following the formation of
nitric oxide [18,19,27,28], possibly similar to that dem-
onstrated to occur in myocardium [23]. However no
studies have yet been conducted to examine this possible
pathophysiological outcome in the pregnant animal.
One final aspect of the present studies was the attempt to
use the hyperglycemic clamp parameters of MPGI, GIR
and MPII [29,34], to define more precisely pregnancy-
induced insulin resistance in sheep. The MPGI was con-
stant across all physiological states and MPII, as an index
of the ewe's pancreatic responsiveness to elevated glucose
concentrations, was reduced in late pregnancy, reflecting
the depressed sensitivity of the pancreas throughout the
hyperglycemic clamp. During the final 40 minutes of the
hyperglycemic clamp, GIR achieved glucose concentra-
tions remained similar between the groups, suggesting
both NPNL ewes and pregnant ewes were utilizing and
extracting available glucose at the same rate, though to
obviously different sinks. This is further supported by the
fact that following a fast, both NPNL and pregnant ewes
had glucose clearance rates not significantly different from
one another. In the present experiments, feed intakes were
not different across pregnant and non-pregnant ewes and
the constant infusion rates suggest similar total utilization
rates, while the difference in MPII reflects different
patterns of glucose utilization. Thus as pregnancy
advances, the site of utilization changes, from peripheral
tissues (muscle and adipose tissues) to the gravid uterus
[13,56]. If there were no mechanisms in place to suppress
peripheral glucose utilization, be it insulin resistance or
reduced insulin output, it should be expected that preg-
nant animals would show a greater GIR and an increased
MPII. Therefore, as GIR was constant across groups and
insulin secretion is suppressed, the peripheral glucose uti-
lization, through the induction of peripheral insulin
resistance, must be depressed in an effort to support glu-
cose homeorhesis during pregnancy.
Conclusions
Increasing NEFA concentrations as gestation advances
provide the maternal compartment with a double advan-
tage. Firstly they act to an alterative fuel source for mater-
nal metabolism. Secondly, they act to promote the
development of an insulin resistant state, which is aided
through the suppression of the glucose-stimulated insulin
release response. This later action is still not well defined
in pregnancy, but could be the result of interactions
between hormones of pregnancy and the maternal pan-
creas, and possibly the result of chronically elevated NEFA
concentrations. Through the development of insulin
resistance in maternal peripheral tissues and a reduced
insulin output, glucose is 'spared' and available for pla-
cental uptake and ultimately, fetal demands.
List of abbreviations as defined in the text
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NPNL Non-pregnant, non lactating
BW Body weight
DM Dry matter
GH Growth hormone
OPL Ovine placental lactogen
AUC Area under curve
CLR Glucose clearance rate
MPGI Mean plasma glucose increment
GIR Glucose infusion rate
MPII Mean plasma insulin increment
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